ViruPOS aciclovir 30 mg/g eye ointment tube

Land: Australien

Sprache: Englisch

Quelle: Department of Health (Therapeutic Goods Administration)

Wirkstoff:

aciclovir, Quantity: 0.135 g

Verfügbar ab:

AFT Pharmaceuticals Pty Ltd

Darreichungsform:

Eye Ointment

Zusammensetzung:

Excipient Ingredients: white soft paraffin

Verabreichungsweg:

Ophthalmic

Einheiten im Paket:

4.5 g

Verschreibungstyp:

(S4) Prescription Only Medicine

Anwendungsgebiete:

Treatment of Herpes simplex keratitis.

Produktbesonderheiten:

Visual Identification: White to white-grey homogenous ointment; Container Type: Tube; Container Material: Epoxy-coated Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Berechtigungsstatus:

Registered

Berechtigungsdatum:

2021-02-11

Gebrauchsinformation

VIRUPOS
EYE OINTMENT ACICLOVIR 3% W/W
WHAT IS IN THIS LEAFLET
This leaflet answers some common questions about ViruPOS eye ointment.
It does not contain all the available
information. It does not take the place of talking to your doctor or
pharmacist.
Please read this leaflet before you start using ViruPOS eye ointment.
If you are helping someone else use
ViruPOS eye ointment, please read this leaflet before using it for the
first time.
All medicines have risks and benefits. Your doctor has weighed the
expected benefits against possible risks of
you using ViruPOS eye ointment. If you have any concerns about using
this medicine, ask your doctor or
pharmacist.
Keep this leaflet with the medicine. You may need to read it again.
WHAT VIRUPOS EYE OINTMENT IS USED FOR
ViruPOS eye ointment contains an antiviral used to treat an eye
infection called herpes simplex keratitis. This
is a viral infection in the eye. It is not used in other infections in
the eye such as conjunctivitis. This medicine is
available only on prescription.
BEFORE YOU USE VIRUPOS EYE OINTMENT
_DO NOT USE VIRUPOS EYE OINTMENT IF:_

you have an allergy to ViruPOS eye ointment, acyclovir, valaciclovir
or any of the ingredients listed at
the
end of this leaflet.

the packaging is torn or shows signs of tampering, or the ointment has
changed colour

it is past the expiry date printed on the pack.

If you use this medicine after the expiry date has passed, it may not
work.

it is more than one month after you first opened the tube of ointment.
If you are not sure whether you should start using ViruPOS eye
ointment, contact your doctor.
Do not give this medicine to anyone else. Your doctor has prescribed
it specifically for you and your condition
only.
_BEFORE YOU START TO USE VIRUPOS EYE OINTMENT_
_ _
TELL YOUR DOCTOR IF:

you have any allergies to any other medicines or any other substances,
such as foods, preservatives or
dyes.

you are pregnant or intend to become pregnant.

you are breastfeeding or planning to breastfeed.
There

Fachinformation

AUSTRALIAN PRODUCT INFORMATION – VIRUPOS (ACICLOVIR) EYE OINTMENT
1
NAME OF THE MEDICINE
Aciclovir
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
White to pale yellow sterile ointment containing 3 per cent w/w
aciclovir in a white soft paraffin base.
For the full list of excipients, see SECTION 6.1 LIST OF EXCIPIENTS.
3
PHARMACEUTICAL FORM
Eye ointment
4
CLINICAL PARTICULARS
4.1
T
HERAPEUTIC INDICATIONS
Treatment of _Herpes simplex _keratitis.
4.2
D
OSE AND METHOD OF ADMINISTRATION
Adults: 1 cm ribbon of ointment should be placed inside the lower
conjunctival sac five times a day at
approximately four hourly intervals. Treatment should be continued for
14 days or at least 3 days after
healing is completed, whichever is shorter.
Children: As for adults.
For individual patient use only.
4.3
C
ONTRAINDICATIONS
Patients with known hypersensitivity to aciclovir or valaciclovir.
4.4
S
PECIAL WARNINGS AND PRECAUTIONS FOR USE
IDENTIFIED PRECAUTIONS
Patients should be informed that transient mild stinging immediately
following application may occur.
Patients should avoid wearing contact lenses when using VIRUPOS eye
ointment.
Resistant strains have been isolated _in vitro _and in animals
following treatment with aciclovir. HSV
strains resistant _in vitro _to aciclovir have also been isolated from
immunocompromised as well as
immuno-competent patients receiving aciclovir for _Herpes simplex
_infections. Therefore, the potential
for the development of resistant HSV strains in patients treated with
aciclovir should be borne in mind.
The relationship between _in vitro _ sensitivity of herpes viruses to
aciclovir and clinical response to
therapy has yet to be established.
USE IN THE ELDERLY
No data available.
Page 1 of 5
PAEDIATRIC USE
No data available.
EFFECTS ON LABORATORY TESTS
No data available.
4.5
I
NTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS
No data available.
4.6
F
ERTILITY
, PREGNANCY AND LACTATION
EFFECTS ON FERTILITY
There is no information on the effect of VIRUPOS on human female
fertility. In a